Biorestorative Therapies

Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures and ThermoStem, which involves the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioRestorative Therapies reports strong Q3 performance and eyes FDA approvals

BioRestorative Therapies (BRTX) showcased strong performance and promising data for BRTX-100 in Q3 2024.
While challenges like patient enrollment and regulatory hurdles exist, opportunities for growth and market entry are abundant.
With a solid financial foundation, management's confidence, and strategic planning, BRTX is poised for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to address several medical conditions , including metabolic disorders such as Obesity, Type 2 Diabetes, Hypertension and other metabolic diseases which capture multi-billion dollar market opportunities.

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

MELVILLE, N.Y., May 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc  . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:  BRTX  ) , a clinical stage company focused on stem cell-based therapies, today announced that it has signed a clinical trial agreement with Northwell Health, New York State's largest health care provider and private employer, and Northwell's Feinstein Institutes for Medical Research. The signing of the agreement will allow Northwell Health to participate in BioRestorative Therapies ongoing Phase 2 clinical trial targeting chronic lumber disc disease (cLDD).

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company's Phase 2 Clinical Trial

MELVILLE, NY., May 04, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference taking place May 10th to 11th at the Plaza Hotel in New York City.

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

-- Clinical data from safety run-in scheduled to be released in second half of 2023 .—

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

Bruder Consulting & Venture Group engaged to expand BRTX-100 c linical indication p ipeline

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

Melville, NY., March 07, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35th Annual Conference being held from March 12 – 14 at The Ritz Carlton, Laguna Niguel in Dana Point, California.

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

Although it's a small biotechnology business, BioRestorative Therapeutics (NASDAQ: BRTX ) is turning heads on Wall Street today. Indeed, BRTX stock is flying high after BioRestorative Therapeutics disclosed a notice of allowance for a patent application from the U.S. Patent and Trademark Office (PTO).

BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News

Biophytis S.A

Diversified Healthcare Trust

Sonoma Pharmaceuticals

Troika Media Group

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch With Big News This Week

--Notice of allowance will be the third US patent to issue from this ThermoStem ® family targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company's metabolic ThermoStem® program. The notice of allowance was issued on February 24, 2023.

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

-- Patent provides protection in key international markets for BioRestorative ' s ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes -- MELVILLE, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the Company's metabolic ThermoStem® program. The notice of allowance was issued on February 6, 2023.

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology.

BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event

-- Non-Dilutive Grant F unding to S upport D evelopment of B rown A dipose- B ased T herapeutic P rograms D irected at P olycystic O vary S yndrom e -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health. This collaborative research will be conducted in partnership with Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University, School of Medicine, Dr. Wu has received numerous national and international awards such as the Women in Endocrinology Young Investigator Award, Eugenia Rosemberg Abstract Award, Early Investigator Award from the Endocrine Society; Virendra B. Mahesh Award of Excellence in Endocrinology, and Endocrinology and Metabolism Section New Investigator Award from American Physiology Society.

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones -- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company” ) (NASDAQ : BRTX ), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive. The intellectual property now exclusively licensed to the Company represents important technological framework for BRTX's disc/spine technology related to the Company's BRTX-100® lead clinical program, currently in a Phase 2 trial with approximately 15 sites selected across the United States. The intellectual property was developed in the lab of Dr. Christopher Centeno. Dr. Centeno has been a leader in the field of cellular therapy for musculoskeletal indications for over 17 years.

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

Melville, NY., Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio Show to discuss the Company's progress and updates on its clinical development pipeline.

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

MELVILLE, NY., Sept. 27, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022. Company management will also be participating in one-on-one meetings throughout the conference.

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

First Patient Enroll ment Milestone Completed

BioRestorative Therapies Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Center for Clinical Research, which is located in North Carolina, is BioRestorative's second clinical trial contract executed.

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

-- First Site Will Enroll First Patient in the Clinical Study--  MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first clinical site to be initiated. Additional selected sites are expected to be initiated in 2022.

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting in Uniondale, NY on April 29th - 30th, 2022 for the Company's lead clinical candidate BRTX-100®, an autologous bone marrow-derived hypoxic cultured stem cell intended for investigational use in its Phase 2 clinical trial to treat chronic lumbar disc disease.

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial targeting chronic lumbar disc disease.

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

MELVILLE, N.Y., March 10, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson, Professor of the Department of Molecular Biosciences, at the Wenner-Gren Institute, at Stockholm University.

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

Notice of Allowance Grants Protection for BioRestorative's Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease

News for Biorestorative Therapies Stock (BRTX)